

Deep and Diverse Pipeline Across CNS and Rare Disease



PROGRAM	INDICATION	PROPOSED MECHANISM OF ACTION	DISCOVERY	IND ENABLING	PHASE 1	PHASE 2	PHASE 3	LAUNCHED
CNS								
NUPLAZID ¹	Parkinson's Disease Psychosis	5HT _{2A} inverse agonist and antagonist						
ACP-204 ⁴	Alzheimer's Disease Psychosis	New 5HT _{2A} inverse agonist						
ACP-204 ⁴	Lewy Body Dementia w/ Psychosis	New 5HT _{2A} inverse agonist						
ACP-711 ^{4,5}	Essential Tremor	Selective GABA _A -α ₃ modulator						
RARE DISEASE								
DAYBUE ²	Rett Syndrome	Analogue of GPE						
ACP-101 ^{3,4}	Hyperphagia in Prader-Willi Syndrome	Intranasal Carbetocin						
ACP-2591 ⁴	Rett Syndrome; Fragile X Syndrome	cGP analogue						
STOKE ASO 1 ^{4,6}	Rett Syndrome	Antisense oligonucleotide (ASO)						
STOKE ASO 2 ^{4,6}	SYNGAP1	Antisense oligonucleotide (ASO)						
STOKE ASO 3 ^{4,6}	Not disclosed	Antisense oligonucleotide (ASO)						
CNS/RARE DISEASE								
ACP-211 ⁴	TRD/MDD/Other	NMDA receptor antagonist						
ACP-271 ⁴	Neurology	GPR88 agonist						

+ Multiple undisclosed discovery programs in CNS and rare disease

¹ NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
² Acadia has an exclusive license to develop and commercialize trofinetide worldwide from Neuren Pharmaceuticals. DAYBUE (trofinetide) is only approved in the U.S. by the FDA and in Canada by Health Canada for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
³ Acadia acquired Levo Therapeutics and its rights/licenses to ACP-101.
⁴ Investigational agents, for which the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.
⁵ Acadia entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of ACP-711.
⁶ Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases; ASO = Antisense oligonucleotide.